C71T
CANCELLED SECTION 71
05/08/2026
Back to search
Official data from USPTO
NORCELL THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
NORCELL THERAPEUTICS
ST13
US500000079255014Class
5, 42, 44
Filing
79255014
Registration
5887788
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
24
Latest update
06/02/2026
Trademark type
Word
Nice classes
5, 42, 44
Filing date
09/24/2018
Registration date
10/22/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/08/2026
Last transaction
06/02/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
84
Owner location
NO
Examiner
HUSSAIN, TASNEEM
Law office
M90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
N. A. (pessoa física)
Representatives
Plougmann Vingtoft
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and substancespharmaceutical preparations and substances for use in hematologyoncology and for the treatment of cancer; reagents for medical use; medical diagnostic chemicals and medical diagnostic reagents for medical use; antibody-based chemicals and reagents for medical usemonoclonal antibodiesimmuno-radiotherapiesantibody-radionuclide-conjugates; radiotherapies in the nature of chemotherapeutics that have a similar mechanism of action; diagnostic assay test kits for medical use consisting of medical diagnostic chemicals and reagents; biochemical preparationsantibodies for medical diagnostic and therapeutic use
Class 42
Medical and pharmaceutical research and developmentmedical and pharmaceutical research and development in the field of hematologyoncology and the treatment of cancer; conducting clinical trials for othersconducting clinical trials in the field of hematologyoncology and the treatment of cancer; providing medical research and scientific research informationin the field of hematologyoncology and the treatment of cancer
Class 44
Medical services; medical services in the field of healingin particular diagnostic services in the field of hematologyoncology and the treatment of cancer; medical servicesimmuno-radiotherapies and radiotherapies in the field of hematologyoncology and the treatment of cancer
Publications
History of USPTO decisions and trademark events.
24 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/22/2024
FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
03/13/2020
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
02/12/2020
XXCR
GENERIC MADRID TRANSACTION CREATED
02/12/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/22/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
10/22/2019
PUBO
PUBLISHED FOR OPPOSITION
08/06/2019
NPUB
NOTICE OF PUBLICATION
07/17/2019
ALIE
ASSIGNED TO LIE
07/01/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/21/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/18/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/18/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/18/2019
RFNT
REFUSAL PROCESSED BY IB
05/18/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/29/2019
RFRR
REFUSAL PROCESSED BY MPU
04/29/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/06/2019
MAFR
APPLICATION FILING RECEIPT MAILED
04/06/2019
CNRT
NON-FINAL ACTION WRITTEN
04/05/2019
DOCK
ASSIGNED TO EXAMINER
04/02/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/02/2019
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
03/27/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/21/2019
Continuous trademark protection
Get notified about every new filing that threatens NORCELL THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.